Dipeptidyl peptidase IV (CD26) in ischemia-reperfusion injury.

Dipeptidyl peptidases are enzymes that cleave N-terminal dipeptides from peptides with proline at the penultimate position. Dipeptidyl peptidase IV is by far the most extensively studied member of this family of serine proteases. Recently, Zhai et al [1] described a decrease in ischemia/reperfusion injury after lung transplantation by flushing and storage of the graft in a solution with the irriversible DPPIV inhibitor, AB192. [2] The goal of this doctoral thesis is to investigate this positive effect on cellular level by measuring the expression of dipeptidyl peptidases (activity-, protein- and mRNA-level) in primarily islolated lung microvascular endothelial cells and the effect of reduced oxygen tension on the expression levels. Secondly, other possible targets of AB192 are investigated and the therapeutically available DPPIV inhibitors (vildagliptin and sitagliptin) are tested for the same positive effects during ischemia-reperfusion injury.

Keywords:DIPEPTIDYL PEPTIDASE, DIPEPTIDYL PEPTIDASE IV, ISCHEMIA

Disciplines:Immunology, Biomarker discovery and evaluation, Drug discovery and development, Medicinal products, Pharmaceutics, Pharmacognosy and phytochemistry, Pharmacology, Pharmacotherapy, Toxicology and toxinology, Other pharmaceutical sciences

Project type:Collaboration project